BEXMAB study update
Faron Pharmaceuticals Oy (“Faron or Company”) Inside Information: Encouraging Additional Data for Bexmarilimab for the Treatment of Hematological Malignancies – BEXMAB Study Update · Objective response observed in 3 out of 5 patients in the first doublet cohort · 2 of the 3 responders were refractory to prior azacitidine monotherapy · No additional adverse events observed adding bexmarilimab to standard of care · Rapid enrollment into both doublet and triplet combinations · CMO Marie-Louise Fjällskog to discuss further details at The Leukemia & Lymphoma